Mark explains some of the regulation trends in the EU, compared with those in the USA and also shares his thoughts on what advances in biotech regulations we can expect to see in the next decade.

Kennedy Jr., invested in gene-editing technology and is owed substantial advances for several books ... including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics.

While billions pour into pharmaceutical biotech, officials and experts warn there’s much less private investment in products more relevant to the military, like body armor materials, anti-corrosion ...

Investors are already returning to biotech, because of these and many other advances, and this is the best entrance into the new millennium that we as practitioners could have hoped.

Physicists at Loughborough University have made an exciting breakthrough in understanding how to fine-tune the behavior of electrons in quantum materials poised to drive the next generation of ...

corporations and governments develop cutting-edge bioanalytical tools and techniques and as the decoding of the human genome continues to usher in new advances in scientific knowledge and ...

NEW YORK - IO Biotech (IOBT), a clinical-stage biopharmaceutical company valued at $58.63 million, has published results from a preclinical study on its second cancer vaccine candidate, IO112, which ...

The synthetic chromosome includes features that enable researchers to generate genetic diversity on demand, accelerating the development of yeasts with enhanced capabilities for biotechnology ...

Virginia Tech is leading the effort that aims to strengthen bonds between biomedical companies and sector leaders.

(RTTNews) - Moleculin Biotech, Inc. (MBRX), a late-stage pharmaceutical company, has announced the initiation of its Phase 3 MIRACLE trial for Annamycin, a next-generation anthracycline ...

today announced significant advances in its biotechnology breeding program and a groundbreaking partnership during the 4th Sanya International Seed Industry Scientist Conference and 2025 ...

Moleculin Biotech announced significant progress in the development of its drug Annamycin, particularly for relapsed or refractory acute myeloid leukemia (AML). The company has received approval ...